Grantham, Mayo, Van Otterloo & Co (GMO)
BIIB icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Biogen BIIB Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-56,740
Closed -$14.6M – 499
2023
Q3 		$14.6M Sell
56,740
-42,707
-43% -$11.4M 0.07% 219
2023
Q2 		$28.3M Sell
99,447
-41,055
-29% -$12.2M 0.13% 137
2023
Q1 		$39.1M Buy
140,502
+5,400
+4% +$1.49M 0.2% 97
2022
Q4 		$37.4M Sell
135,102
-5,698
-4% -$1.61M 0.2% 104
2022
Q3 		$37.6M Sell
140,800
-400
-0.3% -$85K 0.22% 82
2022
Q2 		$28.8M Buy
141,200
+13,700
+11% +$2.8M 0.16% 133
2022
Q1 		$26.9M Buy
127,500
+28,400
+29% +$6.18M 0.13% 145
2021
Q4 		$23.8M Buy
99,100
+5,700
+6% +$1.47M 0.11% 143
2021
Q3 		$26.4M Buy
93,400
+14,400
+18% +$4.72M 0.13% 136
2021
Q2 		$27.4M Buy
79,000
+6,400
+9% +$1.94M 0.14% 129
2021
Q1 		$20.3M Buy
72,600
+13,924
+24% +$3.76M 0.11% 147
2020
Q4 		$14.4M Buy
58,676
+42,740
+268% +$11M 0.09% 155
2020
Q3 		$4.52M Hold
15,936
– – 0.03% 251
2020
Q2 		$4.26M Sell
15,936
-4,100
-20% -$1.23M 0.03% 267
2020
Q1 		$6.34M Sell
20,036
-9,907
-33% -$3.01M 0.05% 208
2019
Q4 		$8.88M Sell
29,943
-9,067
-23% -$2.52M 0.06% 205
2019
Q3 		$9.08M Sell
39,010
-1,490
-4% -$347K 0.06% 199
2019
Q2 		$9.47M Buy
40,500
+12,200
+43% +$2.82M 0.07% 198
2019
Q1 		$6.69M Buy
28,300
+22,500
+388% +$7.08M 0.05% 226
2018
Q4 		$1.75M Buy
5,800
+200
+4% +$63.8K 0.01% 300
2018
Q3 		$1.98M Sell
5,600
-2,410
-30% -$830K 0.01% 310
2018
Q2 		$2.33M Sell
8,010
-22,190
-73% -$6.24M 0.02% 293
2018
Q1 		$8.27M Buy
30,200
+28,900
+2,223% +$8.97M 0.05% 172
2017
Q4 		$414K Sell
1,300
-180
-12% -$57.7K ﹤0.01% 476
2017
Q3 		$463K Sell
1,480
-23,004
-94% -$6.81M ﹤0.01% 421
2017
Q2 		$6.64M Buy
24,484
+23,004
+1,554% +$6.08M 0.04% 212
2017
Q1 		$405K Buy
+1,480
New +$418K ﹤0.01% 414
2016
Q2 		– Sell
-1,380
Closed -$359K – 571
2016
Q1 		$359K Sell
1,380
-96,954
-99% -$25.6M ﹤0.01% 492
2015
Q4 		$30.1M Sell
98,334
-80,887
-45% -$23.2M 0.11% 135
2015
Q3 		$52.3M Sell
179,221
-71,824
-29% -$23.7M 0.18% 103
2015
Q2 		$101M Sell
251,045
-418,100
-62% -$168M 0.33% 66
2015
Q1 		$283M Sell
669,145
-26,971
-4% -$10.6M 0.84% 26
2014
Q4 		$236M Sell
696,116
-104,185
-13% -$33.7M 0.64% 38
2014
Q3 		$265M Sell
800,301
-57,498
-7% -$19M 0.7% 34
2014
Q2 		$270M Buy
857,799
+380,800
+80% +$115M 0.73% 36
2014
Q1 		$146M Buy
476,999
+340,768
+250% +$108M 0.38% 55
2013
Q4 		$38.1M Sell
136,231
-497
-0.4% -$129K 0.09% 109
2013
Q3 		$32.9M Sell
136,728
-7,773
-5% -$1.74M 0.09% 101
2013
Q2 		$31.1M Buy
+144,501
New +$30.9M 0.08% 98

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s BIIB Position: Q4 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Biogen (BIIB) in Q4 2023, closing a stake of 56,740 shares — an estimated $14.6M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in BIIB in Q2 2013 and held it in 39 quarters. The position peaked at $283M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 56,740 Biogen shares in Q4 2023, an estimated $14.6M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Biogen in Q2 2013 and held it in 39 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Biogen position peaked at $283M in Q1 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2023, filed 13 Feb 2024.